ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

RNAC Cartesian Therapeutics Inc

22.89
1.13 (5.19%)
20 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cartesian Therapeutics Inc NASDAQ:RNAC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.13 5.19% 22.89 22.61 25.27 24.91 21.24 22.00 106,108 21:02:00

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

13/05/2024 9:30pm

GlobeNewswire Inc.


Cartesian Therapeutics (NASDAQ:RNAC)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Cartesian Therapeutics Charts.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 3:00 p.m. ET.

A live webcast of the fireside chat is expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the event will be accessible for a limited time.

About Cartesian TherapeuticsCartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis. Additional Phase 2 studies are planned in systemic lupus erythematosus under an allowed IND, as well as basket trials in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

Contact InformationInvestor Relations:Ron MoldaverRon.moldaver@cartesiantx.com

Media:David RosenArgot Partnerscartesian@argotpartners.com

1 Year Cartesian Therapeutics Chart

1 Year Cartesian Therapeutics Chart

1 Month Cartesian Therapeutics Chart

1 Month Cartesian Therapeutics Chart